An insight to Bentham Science Publishers

Recently published issues in various journals of Bentham Science

Cardiovascular & Hematological Disorders-Drug Targets, 15 Issue 2

Current Topics in Medicinal Chemistry, 16 Issue 10

Current Drug Metabolism, 16 Issue 10

Inflammation & Allergy-Drug Targets, 14 Issue 1

Current Medicinal Chemistry, 22 Issue 37

SMI EVENT – 11th annual ADMET conference on 13 – 14 June, 2016 in Holiday Inn Kensington Forum, London!

SMi is proud to announce the return of the 11th annual ADMET conference 2016 in London!

200x200 copy

This event will explore novel and emerging non-clinical ADME approaches, structure based prediction of ADME properties, PK/PD modelling to validate drug targets, toxicity and much more. ADMET 2016 will provide a series of practical case studies, interactive roundtables and panel discussions facilitated by leading industry experts that will provide executives with useful tools and best practices to: discover application of PBPK to drug development in rare diseases; review the role of drug transporters in drug delivery to CNS diseases; learn about better models for understanding, predicting and avoiding drug induced liver injury; discuss in silico approaches to evidence-based mechanistic modelling and analyse early dose predictions – a valuable tool in risk assessment and optimisation of small molecules. The agenda features leading industry experts from likes of Roche, Sanofi-Aventis, GSK, UCB Pharma, Genentech, Merck Serono, Lundbeck and many more.

For further information visit the event website

“Anti-Monopoly and Competition Laws – Impact on the Indian Pharmaceutical Industry”

Monopoly in Pharmaceuticals Hazardous for the Society!

In every country, developed or developing, the markets for every industry need to be properly regulated in order to control the dynamics of that market. Monopoly or monopolistic competition, both, prove detrimental for the industry as a whole for the reason that it allows a few players to hold the reigns of research, trade and the overall impact on the stakeholders, primarily the customers.

When we talk about pharmaceutical industry, this concept becomes even more sensitive. Pharmaceuticals deal with medicines that are meant to cure diseases for the ailing members of the population. It requires continuous research, heavy funding, very smooth supply chain and extremely strong check on the prices for medicines. The potential messiahs, the medicines, have to be well within the reach and affordability of the people. At the same time the prices have to generate profits for the pharmaceutical firms.


Hence the regulatory bodies have to be very active and vigilant in controlling and yet growing healthy competition among the firms. This can be done through constant reviewing, updating and good execution of the laws and acts that the experts in these bodies devise.

Researchers from the University of Rohtak, India give an example of how the regulatory bodies and their devised Acts work to maintain healthy competition among pharmaceuticals in the paper, Anti-Monopoly and Competition Laws – Impact on the Indian Pharmaceutical Industry. The research paper is published in the journal, Applied Clinical Research, Clinical Trials and Regulatory Affairs.

SMI EVENT ::: 10th annual Clinical Trial Logistics in London from 18-19 May, 2016

SMi proudly presents the return of the 10th annual Clinical Trial Logistics to London in 2016.

200 x 200

SMi’s 10th annual Clinical Trial Logistics event will provide the perfect platform to raise and discuss the challenges associated since the implementation of annex 15 of the Good Manufacturing Practice in Autumn 2015. The implementation of the annex provided a huge change in the regulatory landscape of the rapidly growing clinical trial supplies industry, with logistics and distribution services segments accounting for the largest share of the market. Moreover, this conference will aim to address uncertainties and examine best practices to ensure compliance of the new EU Clinical Trials Regulation. Speakers include Daiichi Sankyo, GlaxoSmithKline, MHRA, Merck Sharp & Dohme, Sanofi and many more.

For more information or to register visit

Press Release ::: New podcasts uploaded on Bentham Science YouTube Channel in January 2016

Dubai, UAE: February 01, 2016: Five new podcasts have been uploaded on Bentham Science YouTube Channel. You can watch the podcasts by clicking on the links below:

For more exclusive podcasts by our authors on journal articles and eBooks, please subscribe to our YouTube channel:

New Issue ::: Applied Clinical Research, Clinical Trials and Regulatory Affairs

Applied Clinical Research, Clinical Trials and Regulatory Affairs is an international journal with market leadership in readership and contributions that are scientific, original, relevant, innovative and statistically validated. The journal aims to further bridge the gap in the publication of clinical drug development and regulatory affairs between high growth and potentially growing regions.

Articles from the journal Applied Clinical Research, Clinical Trials and Regulatory Affairs, Volume 2 Issue 2:

  • Mammalian Fertilization: Scientific Basis and Recent Progress
  • Post-Approval Changes in Pharmaceuticals: Regulatory Perspectives in Europe
  • Physical and Mechanical Therapies for Lower Limb Problems in Juvenile Idiopathic Arthritis: A Systematic Review (Protocol)
  • Periodontal Disease and Potential Association with Systemic Diseases and Conditions (Mini-review)
  • Transparency in Clinical Research and Status in Turkey & Middle East
  • Obesity- An Adverse Factor in Reproductive Age
  • Disease Registries: Challenges and Opportunities to Realize Their Full Potential
  • A Rapid LC-ESI-MS/MS Method for the Quantitation of Salicylic Acid, an Active Metabolite of Acetylsalicylic Acid: Application to in vivo Pharmacokinetic and Bioequivalence Study in Indian Healthy Male Volunteers
  • Evaluation of a Genetic Counseling Aid for Hereditary Breast and Ovarian Cancer
  • The Status of Disease Registries in the United States: Reflections
For details on the articles, please visit this link ::



What Does Jupiter Mean To Earth – Protector or Aggressor?

Our universe is a peculiar place with loads of surprises lurking around, only to reveal themselves as we keep digging into their reality. The planet Jupiter is one such being in our solar system that comes under debate way more often. At first, it was believed that this gigantic planet is a calm, composed, gentle being with little happening on it. This idea got replaced as the scientists discovered explosions occurring on its surface.

Similarly, another myth that prevailed was that Jupiter has been entirely benevolent for our planet Earth and keeping away the loose debris in our galaxy from reaching us. In 1994, this myth got stronger when Jupiter broke and consumed a comet on the way to crash on Earth. Jupiter’s extraordinary gravitational field is fully capable of deviating paths and directing objects roaming around nearby. But scientists have recently debunked this idea as well to some extent. Now it is studied that Jupiter does influence the motion of objects but it actually pushes them towards the inner orbits of the solar system where Earth happens to rotate. In fact, thanks to this moody giant, many a planetismals changed paths and collided to expand the size of our planet in the earliest times.


This sounds dangerous to get comets targeted towards Earth but it also had a very positive side. These masses carried many elements that contributed to the emergence of life. They carry Hydrogen, Nitrogen, Carbon dioxide etc. which are essential ingredients for living beings. These elements also help keep Earth warm and thus are much needed.

This finding made it more difficult for us, Earth dwellers, to decide whether Jupiter is a friend or foe for our planet.

Most Cited Article :: Sunflower Trypsin Inhibitor 1


Current Protein & Peptide Science, 5(5): 351-364.

Author(s): Michael L.J. Korsinczky, Horst Joachim Schirra and David J Craik.


SFTI-1 is a bicyclic 14 amino acid peptide that was originally isolated from the seeds of the sunflower Helianthus annuus. It is a potent inhibitor of trypsin, with a sub-nanomolar Ki value and is homologous to the active site region of the well-known family of serine protease inhibitors known as the Bowman-Birk trypsin inhibitors. It has a cyclic backbone that is cross-braced by a single disulfide bridge and a network of hydrogen bonds that result in a well-defined structure. SFTI-1 is amenable to chemical synthesis, allowing for the creation of synthetic variants. Alterations to the structure such as linearising the backbone or removing the disulfide bridge do not reduce the potency of SFTI-1 significantly, and minimising the peptide to as few as nine residues results in only a small decrease in reactivity. The creation of linear variants of SFTI-1 also provides a tool for investigating putative linear precursor peptides. The mechanism of biosynthesis of SFTI-1 is not yet known but it seems likely that it is a gene-coded product that has arisen from a precursor protein that may be evolutionarily related to classic Bowman-Birk inhibitors.

Read more here:

EurekAlert ::: A disposable, highly sensitive biosensing system

Determination of haptoglobin as a significant acute phase biomarker

We are pleased to announce that a new biosensing platform has been fabricated for the determination of Haptoglobin in human blood.

Haptoglobin (Hp) is a glycoprotein and is produced as an acute phase plasma component and synthesized in many different tissues. The glycoprotein has many biochemical and metabolic roles such as hosting defence responses to infection and inflammation, acting as an antioxidant, antibacterial and anti-inflammatory roles, and as an inhibitor of prostaglandin synthesis. Moreover, it is reported that the levels of Hp are elevated in neuromyelitisoptica. Because of the metabolic importance of Hp, its sensitive and selective analysis is also of vital importance to researchers.

In this research, a highly sensitive and disposable Indium Tin Oxide (ITO) based biosensing tool was developed. Featuring the considerable superiorities of ITO substrates, suitability for disposable biosensors, low cost, and repeatability, a novel anti-Hp based biosensor was created with a very low detection limit. Anti-Hp antibody was utilized in this research for fabrication of such a disposable biosensor integrated with ITO substrates for the first time. The new biosensor presents highly analytical performance with a linear range 0.2 fg/mL – 1fg/mL. Kramers-Kronig Transform was performed on the experimental impedance data. The single frequency impedance technique was first used for characterization of interaction between Haptoglobin and anti-Haptoglobin.

Our research suggests that ITO substrates can be used in other biosensing strategies with high reproducibility and repeatability. Besides, the single frequency impedance technique can be performed in the evaluation of association and dissociation relations of bimolecular interactions, successfully.


Prof. Dr. Mustafa K Sezgintürk
Dr. Münteha N. Sonuç
Nam?k Kemal University, Faculty of Science, Chemistry Department,
Tekirda?, Turkey

Read more:

Blog at | The Baskerville Theme.

Up ↑


Get every new post delivered to your Inbox.

Join 6,272 other followers

%d bloggers like this: